Valomaciclovir

DB06575

small molecule investigational

Deskripsi

Struktur Molekul 2D

Berat 352.395
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

369 Data
Regadenoson Valomaciclovir may decrease effectiveness of Regadenoson as a diagnostic agent.
Adalimumab The serum concentration of Valomaciclovir can be decreased when it is combined with Adalimumab.
Adenosine The therapeutic efficacy of Adenosine can be decreased when used in combination with Valomaciclovir.
Allopurinol The serum concentration of Valomaciclovir can be increased when it is combined with Allopurinol.
Carbamazepine The serum concentration of Valomaciclovir can be decreased when it is combined with Carbamazepine.
Cimetidine The metabolism of Valomaciclovir can be decreased when combined with Cimetidine.
Disulfiram The serum concentration of Valomaciclovir can be increased when it is combined with Disulfiram.
Febuxostat The serum concentration of the active metabolites of Valomaciclovir can be increased when Valomaciclovir is used in combination with Febuxostat.
Fluvoxamine The metabolism of Valomaciclovir can be decreased when combined with Fluvoxamine.
Formoterol The risk or severity of hypokalemia can be increased when Valomaciclovir is combined with Formoterol.
Indacaterol The risk or severity of adverse effects can be increased when Valomaciclovir is combined with Indacaterol.
Isoniazid The serum concentration of Valomaciclovir can be increased when it is combined with Isoniazid.
Lithium citrate The serum concentration of Lithium citrate can be decreased when it is combined with Valomaciclovir.
Lithium carbonate The serum concentration of Lithium carbonate can be decreased when it is combined with Valomaciclovir.
Lithium hydroxide The serum concentration of Lithium hydroxide can be decreased when it is combined with Valomaciclovir.
Mexiletine The metabolism of Valomaciclovir can be decreased when combined with Mexiletine.
Olodaterol Valomaciclovir may increase the hyperkalemic activities of Olodaterol.
Pancuronium The therapeutic efficacy of Pancuronium can be decreased when used in combination with Valomaciclovir.
Pentoxifylline The serum concentration of Valomaciclovir can be increased when it is combined with Pentoxifylline.
Phenytoin The serum concentration of Valomaciclovir can be decreased when it is combined with Phenytoin.
Fosphenytoin The serum concentration of Valomaciclovir can be decreased when it is combined with Fosphenytoin.
Propafenone The serum concentration of Valomaciclovir can be increased when it is combined with Propafenone.
Quinine The serum concentration of Valomaciclovir can be increased when it is combined with Quinine.
Quinidine The serum concentration of Valomaciclovir can be increased when it is combined with Quinidine.
Riociguat Valomaciclovir may increase the hypotensive activities of Riociguat.
Thiabendazole The metabolism of Valomaciclovir can be decreased when combined with Thiabendazole.
Ticlopidine The metabolism of Valomaciclovir can be decreased when combined with Ticlopidine.
Zafirlukast The serum concentration of Zafirlukast can be decreased when it is combined with Valomaciclovir.
Probenecid The serum concentration of Valomaciclovir can be increased when it is combined with Probenecid.
Isoprenaline The serum concentration of Valomaciclovir can be decreased when it is combined with Isoprenaline.
Amphetamine The risk or severity of adverse effects can be increased when Amphetamine is combined with Valomaciclovir.
Phentermine The risk or severity of adverse effects can be increased when Phentermine is combined with Valomaciclovir.
Midodrine The risk or severity of adverse effects can be increased when Midodrine is combined with Valomaciclovir.
Norepinephrine The risk or severity of adverse effects can be increased when Norepinephrine is combined with Valomaciclovir.
Phenylephrine The risk or severity of adverse effects can be increased when Phenylephrine is combined with Valomaciclovir.
Phenylpropanolamine The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Valomaciclovir.
Labetalol The risk or severity of adverse effects can be increased when Labetalol is combined with Valomaciclovir.
Metaraminol The risk or severity of adverse effects can be increased when Metaraminol is combined with Valomaciclovir.
Epinephrine The risk or severity of adverse effects can be increased when Epinephrine is combined with Valomaciclovir.
Methoxamine The risk or severity of adverse effects can be increased when Methoxamine is combined with Valomaciclovir.
Orciprenaline The risk or severity of adverse effects can be increased when Orciprenaline is combined with Valomaciclovir.
Phenmetrazine The risk or severity of adverse effects can be increased when Phenmetrazine is combined with Valomaciclovir.
Dobutamine The risk or severity of adverse effects can be increased when Dobutamine is combined with Valomaciclovir.
Pseudoephedrine The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Valomaciclovir.
Benzphetamine The risk or severity of adverse effects can be increased when Benzphetamine is combined with Valomaciclovir.
Ritodrine The risk or severity of adverse effects can be increased when Ritodrine is combined with Valomaciclovir.
Terbutaline The risk or severity of adverse effects can be increased when Terbutaline is combined with Valomaciclovir.
Oxymetazoline The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Valomaciclovir.
Diethylpropion The risk or severity of adverse effects can be increased when Diethylpropion is combined with Valomaciclovir.
Dopamine The risk or severity of adverse effects can be increased when Dopamine is combined with Valomaciclovir.
Acebutolol The risk or severity of adverse effects can be increased when Acebutolol is combined with Valomaciclovir.
Lisdexamfetamine The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Valomaciclovir.
Fenoterol The risk or severity of adverse effects can be increased when Fenoterol is combined with Valomaciclovir.
Ephedrine The risk or severity of adverse effects can be increased when Ephedrine is combined with Valomaciclovir.
Mephentermine The risk or severity of adverse effects can be increased when Mephentermine is combined with Valomaciclovir.
Procaterol The risk or severity of adverse effects can be increased when Procaterol is combined with Valomaciclovir.
Clenbuterol The risk or severity of adverse effects can be increased when Clenbuterol is combined with Valomaciclovir.
MMDA The risk or severity of adverse effects can be increased when MMDA is combined with Valomaciclovir.
Midomafetamine The risk or severity of adverse effects can be increased when Midomafetamine is combined with Valomaciclovir.
2,5-Dimethoxy-4-ethylamphetamine The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Valomaciclovir.
4-Bromo-2,5-dimethoxyamphetamine The risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Valomaciclovir.
Tenamfetamine The risk or severity of adverse effects can be increased when Tenamfetamine is combined with Valomaciclovir.
Chlorphentermine The risk or severity of adverse effects can be increased when Chlorphentermine is combined with Valomaciclovir.
Methylenedioxyethamphetamine The risk or severity of adverse effects can be increased when Methylenedioxyethamphetamine is combined with Valomaciclovir.
Dextroamphetamine The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with Valomaciclovir.
Metamfetamine The risk or severity of adverse effects can be increased when Metamfetamine is combined with Valomaciclovir.
Celiprolol The risk or severity of adverse effects can be increased when Celiprolol is combined with Valomaciclovir.
Nylidrin The risk or severity of adverse effects can be increased when Nylidrin is combined with Valomaciclovir.
Tetryzoline The risk or severity of adverse effects can be increased when Tetryzoline is combined with Valomaciclovir.
Tyramine The risk or severity of adverse effects can be increased when Tyramine is combined with Valomaciclovir.
Isoxsuprine The risk or severity of adverse effects can be increased when Isoxsuprine is combined with Valomaciclovir.
Etilefrine The risk or severity of adverse effects can be increased when Etilefrine is combined with Valomaciclovir.
Synephrine The risk or severity of adverse effects can be increased when Synephrine is combined with Valomaciclovir.
Hydroxyamphetamine The risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Valomaciclovir.
Iofetamine I-123 The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Valomaciclovir.
Racepinephrine The risk or severity of adverse effects can be increased when Racepinephrine is combined with Valomaciclovir.
Ritobegron The risk or severity of adverse effects can be increased when Ritobegron is combined with Valomaciclovir.
Bucindolol The risk or severity of adverse effects can be increased when Bucindolol is combined with Valomaciclovir.
Tramazoline The risk or severity of adverse effects can be increased when Tramazoline is combined with Valomaciclovir.
Mephedrone The risk or severity of adverse effects can be increased when Mephedrone is combined with Valomaciclovir.
Fenozolone The risk or severity of adverse effects can be increased when Fenozolone is combined with Valomaciclovir.
Methoxyphenamine The risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Valomaciclovir.
Tretoquinol The risk or severity of adverse effects can be increased when Tretoquinol is combined with Valomaciclovir.
Gepefrine The risk or severity of adverse effects can be increased when Gepefrine is combined with Valomaciclovir.
Epanolol The risk or severity of adverse effects can be increased when Epanolol is combined with Valomaciclovir.
Prenalterol The risk or severity of adverse effects can be increased when Prenalterol is combined with Valomaciclovir.
Mefenorex The risk or severity of adverse effects can be increased when Mefenorex is combined with Valomaciclovir.
2,5-Dimethoxy-4-ethylthioamphetamine The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Valomaciclovir.
Esmolol The risk or severity of adverse effects can be increased when Esmolol is combined with Valomaciclovir.
Betaxolol The risk or severity of adverse effects can be increased when Betaxolol is combined with Valomaciclovir.
Metoprolol The risk or severity of adverse effects can be increased when Metoprolol is combined with Valomaciclovir.
Atenolol The risk or severity of adverse effects can be increased when Atenolol is combined with Valomaciclovir.
Timolol The risk or severity of adverse effects can be increased when Timolol is combined with Valomaciclovir.
Sotalol The risk or severity of adverse effects can be increased when Sotalol is combined with Valomaciclovir.
Propranolol The risk or severity of adverse effects can be increased when Propranolol is combined with Valomaciclovir.
Bisoprolol The risk or severity of adverse effects can be increased when Bisoprolol is combined with Valomaciclovir.
Alprenolol The risk or severity of adverse effects can be increased when Alprenolol is combined with Valomaciclovir.
Pindolol The risk or severity of adverse effects can be increased when Pindolol is combined with Valomaciclovir.
Carvedilol The risk or severity of adverse effects can be increased when Carvedilol is combined with Valomaciclovir.
Bevantolol The risk or severity of adverse effects can be increased when Bevantolol is combined with Valomaciclovir.

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul